US Stock MarketDetailed Quotes
BCLI Brainstorm Cell Therapeutics
- 0.352
- -0.014-3.93%
Close Jul 26 16:00 ET
- 0.355
- +0.003+0.97%
Post 20:02 ET
27.98MMarket Cap-1134P/E (TTM)
0.379High0.350Low141.86KVolume0.365Open0.366Pre Close50.92KTurnover0.20%Turnover RatioLossP/E (Static)79.58MShares1.90052wk High-5.02P/B25.25MFloat Cap0.13452wk Low--Dividend TTM71.82MShs Float52.500Historical High--Div YieldTTM8.01%Amplitude0.134Historical Low0.358Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg
Brainstorm Cell Therapeutics Stock Forum
BCLI Update - Progress Supports Our 10x Plus Value Range PotentialBCLIShare
ACF Equity Research
FROM ACF EQUITY RESEARCH HEALTHCARE TEAM
LONDON, July 24, 2024 /PRNewswire/ --
NASDAQ: BCLI
READ ACF EQUITY RESEARCH'S UPDATE NOTE HERE
READ ACF EQUITY RESEARCH'S RELATED THEMATIC RESEARCH NOTE ON REGENERATIVE MEDICINE – NEURODEGENERATIVE DISEASE STEM CELLS & ALS/MND/LOU GEHRIG'S HERE
UPDATE NOTE: BrainStorm Cell Therapeutics...
BrainStorm Cell Therapeutics Reaches Alignment with FDA on CMC Aspects of Phase 3b NurOwn® Clinical Trial
BrainStorm Cell Therapeutics (NASDAQ: BCLI) has reached alignment with the FDA on the Chemistry, Manufacturing, and Controls (CMC) aspects of its Phase 3b clinical trial for NurOwn, a therapy for amyotrophic lateral sclerosis (ALS). This development follows the FDA’s Special Protocol Assessment (SPA) agreement granted in April 2024, which provided ...
⚫️BCLI's primary target is the fatal amyotrophic lateral sclerosis (ALS/MND/Lou Gehrig's).
▪️Post hoc analysis of BCLI's PIII trial data shows BCLI's NurOwn® (debamestrocel, MSC-NTF), has STATISTICALLY SIGNIFICANT clinical effects on early-stage ALS sufferers and that placebo trialists deteriorate faster.
▪️Peer reviewed research (Mar 2024) indicated that BCLI's NurOwn® has a positive impact on NfL biomarkers...
No comment yet